Psoriasis

FDA approves ustekinumab for pediatric psoriasis
August 07, 2020

The U.S. Food and Drug Administration has approved IL-12/IL-23 inhibitor ustekinumab (Stelara, Janssen Pharmaceutical Companies of Johnson & Johnson) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6-11 years.

The Cutaneous Connection: Episode 4- Probiotics for Psoriasis?
August 06, 2020

This episode dives into emerging research regarding probiotics specifically tailored to treat psoriasis and possibly other inflammatory skin diseases.

EC approves secukinumab for pediatric psoriasis
August 04, 2020

The European Commission has approved secukinumab (Cosentyx, Novartis) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6